ArticleThe International journal of artificial organs2026
Clinical and metabolic outcomes of artificial pancreas systems in patients with type 1 diabetes: A real-world study.
Article in The International journal of artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionArtificial pancreas systems represent an important technological advancement in the management of type 1 diabetes mellitus (T1DM). These systems provide automated insulin delivery and have the potential to improve glycemic control and cardiometabolic outcomes. In this study, we aimed to evaluate the effects of artificial pancreas systems on glycemic control, lipid parameters, and proteinuria in patients with T1DM in a real-world clinical setting.
methodsThis retrospective study included 32 patients with T1DM who transitioned to artificial pancreas therapy. Glycemic parameters including HbA1c, fasting blood glucose (FBG), and postprandial blood glucose (PBG) were compared before pump initiation and at 3 months, 6 months, and 1 year after treatment. Lipid parameters and spot urine proteinuria levels were evaluated before pump therapy and at 1-year follow-up. Repeated measures ANOVA and paired t-tests were used for continuous variables, while Cochran's Q and McNemar tests were used for categorical variables.
resultsA significant reduction in HbA1c levels was observed over time, decreasing from 8.74 ± 1.21% before pump initiation to 7.92 ± 0.98% at 3 months, 7.61 ± 0.87% at 6 months, and 7.48 ± 0.83% at 1 year (
conclusionArtificial pancreas therapy significantly improves glycemic control and increases the proportion of patients achieving HbA1c targets in individuals with T1DM. In addition, favorable effects on lipid profile and proteinuria suggest potential cardiometabolic benefits of artificial pancreas systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.